Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the...

Related Keywords

Switzerland ,Melbourne ,Victoria ,Australia ,San Antonio ,Texas ,United States ,Belgium ,United Kingdom ,Japan ,Canada ,American ,Australian ,Christian Behrenbruch ,Kyahn Williamson ,Caroline Rousseau ,Australian Therapeutic Goods Administration ,World Cancer Research Fund ,Health Canada ,American Cancer Society ,Telix Pharmaceuticals ,Corporate Communications ,Drug Administration ,Australian Securities Exchange ,Telix Pharmaceuticals Limited ,Antonio Breast Cancer ,Institut De Canc ,Managing Director ,Triple Negative Breast Cancer ,Innovation Unit ,European Economic Area ,Cancer Research Fund ,Cancer Society ,